Uveitis

In this video from the virtual American Society of Retina Specialists meeting, Dilraj Grewal, MD, MBBS, discusses a study evaluating the recurrence of uveitis after treatment with the Yutiq insert from EyePoint Pharmaceuticals.

A large proportion of patients with uveitis who are undergoing cataract surgery may have refractive outcomes that deviate from the intended target.

Children with rheumatic disease who are at high risk for chronic uveitis, or have a history of uveitis, should continue to receive routine ophthalmologic surveillance on schedule through in-person visits, with slit lamp examination, according to COVID-19 clinical guidance from the American College of Rheumatology.

Tocilizumab failed to meet its primary endpoint of treatment response in patients with uveitis associated with juvenile idiopathic arthritis, according to phase 2 trial findings published in The Lancet Rheumatology.

Complex, multifactorial and associated with at least 40 different disorders, uveitis is the fifth leading cause of blindness worldwide. With an estimated 30,000 new cases each year, it is responsible for about 10% to 15% of all cases of legal blindness in the United States.

The accompanying cover story on uveitis is quite comprehensive, and I have only a few thoughts to add.

KOLOA, Hawaii — Retina specialists are “uniquely qualified and skilled” to care for patients with uveitis, Sunil K. Srivastava, MD, told attendees at Retina 2020.

Drugs that treat systemic diseases can be lifesaving, but when these drugs lead to poor ocular health or vision, the treatment paradigms can be difficult to balance. When a systemic disease and its treatment are negatively affecting vision, hard choices need to be made.

Switching to a biosimilar would be a “feasible treatment choice,” and is associated with maintaining clinical efficacy in patients with noninfectious uveitis who previously received the reference biologic, according to data published in Frontiers in Pharmacology.

Switching to a biosimilar would be a “feasible treatment choice,” and is associated with maintaining clinical efficacy in patients with noninfectious uveitis who previously received the reference biologic, according to data published in Frontiers in Pharmacology.